PharmaCyte Biotech Ready to Submit Investigational New Drug Application to FDA for Clinical Trial in Pancreatic Cancer
03. August 2020 09:00 ET
|
PharmaCyte Biotech
NEW YORK, NY, Aug. 03, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has reached what can only be described as a momentous milestone in its history and what should be considered a...
PharmaCyte Biotech’s COVID-19 Test Offers “Pool Testing” Dr. Fauci and White House Coronavirus Task Force Now Considering
29. Juni 2020 06:55 ET
|
PharmaCyte Biotech
NEW YORK, NY, June 29, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) may have what the White House Coronavirus Task Force is looking for just as COVID-19 cases are surging across the...
Developer of PharmaCyte Biotech’s COVID-19 Test Explains Why His Test Is So Highly Sensitive, Path to FDA EUA, and Commercialization
20. April 2020 09:00 ET
|
PharmaCyte Biotech
NEW YORK, NY, April 20, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) recently entered into a licensing agreement with Hai Kang Life Corporation (Hai Kang), where Hai Kang granted to...
PharmaCyte Biotech to Offer COVID-19 Testing While Creating Revenue Stream for Pancreatic Cancer Program
13. April 2020 09:00 ET
|
PharmaCyte Biotech
NEW YORK, NY, April 13, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) is a California-based biotechnology company focused on developing cellular therapies for cancer and diabetes using...
PharmaCyte Biotech CEO Discusses Navigating Testing and IND Submission During COVID-19 Pandemic
26. März 2020 09:00 ET
|
PharmaCyte Biotech
NEW YORK, NY, March 26, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) continues to work with consultants to prepare its Investigational New Drug application (IND). At the same time,...
PharmaCyte Biotech Will Have All the Protection It Needs for Pancreatic Cancer Treatment Upon Marketing Approval
04. Februar 2020 09:00 ET
|
PharmaCyte Biotech
NEW YORK, NY, Feb. 04, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) is about to embark upon a planned U.S. FDA Phase 2b clinical trial to treat locally advanced, inoperable pancreatic...
PharmaCyte Biotech’s Pancreatic Cancer Therapy Passes Critical FDA-Required Tests as Countdown to IND Submission Begins
27. Januar 2020 09:00 ET
|
PharmaCyte Biotech
NEW YORK, NY, Jan. 27, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) announced that its clinical trial product, which will be employed during the company’s upcoming Phase 2b clinical...
PharmaCyte Biotech Addressing Unmet Need in Patients with LAPC as Pancreatic Cancer 5-Year Survival Rate Increases to 10%
14. Januar 2020 09:00 ET
|
PharmaCyte Biotech
NEW YORK, NY, Jan. 14, 2020 (GLOBE NEWSWIRE) -- This month the American Cancer Society announced that for the first time ever, the 5-year survival rate for pancreatic cancer has reached double...
PharmaCyte Biotech Set to Reach Three Major Milestones in 2020
06. Januar 2020 09:00 ET
|
PharmaCyte Biotech
NEW YORK, NY, Jan. 06, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech’s (OTCQB: PMCB) shareholders should expect 2020 to be the year that ushers in a host of much-anticipated milestones. This year the...
PharmaCyte Biotech Finalizes Pancreatic Cancer Treatment for U.S. FDA Approval to Begin Clinical Trial
11. Dezember 2019 09:00 ET
|
PharmaCyte Biotech
NEW YORK, NY, Dec. 11, 2019 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has a clinical trial product, a clinical trial protocol, including a clinical trial design, a Principal Investigator,...